Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aileron Therapeutics Inc ALRN

Healthcare Biotechnology
Aileron Therapeutics, Inc. is a biopharmaceutical company. The Company is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib... see more

Recent & Breaking News (NDAQ:ALRN)

Aileron Therapeutics to Present at the Canaccord Genuity 38th Annual Growth Conference

GlobeNewswire August 2, 2018

Aileron Therapeutics to Report Second Quarter 2018 Financial Results on August 7, 2018

GlobeNewswire July 31, 2018

Aileron Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference

GlobeNewswire May 29, 2018

Benzinga's Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck's Cancer Drug Review Extended

Benzinga.com  May 25, 2018

Aileron Therapeutics Announces Changes to Management

GlobeNewswire May 15, 2018

Aileron Therapeutics Reports First Quarter 2018 Financial Results

GlobeNewswire May 9, 2018

Benzinga's Daily Biotech Pulse: Intra-cellular Moves On Poster Presentation, Earnings Beats From Vertex, Exact Sciences

Benzinga.com  April 27, 2018

32 Biggest Movers From Yesterday

Benzinga.com  April 20, 2018

Aileron Therapeutics Announces Publication by Researchers at Albert Einstein College of Medicine of ALRN-6924 Nonclinical Data in Acute Myeloid Leukemia

GlobeNewswire April 11, 2018

Aileron Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

GlobeNewswire April 2, 2018

Aileron Therapeutics Announces Expansion of Scientific Advisory Board

GlobeNewswire March 28, 2018

Aileron Therapeutics Appoints Jeffrey A. Bailey to its Board of Directors

GlobeNewswire March 19, 2018

30 Biggest Movers From Yesterday

Benzinga.com  December 28, 2017

Aileron Therapeutics Presents New Data on ALRN-6924 in Oral Presentations at 2017 American Society of Hematology Meeting

GlobeNewswire December 11, 2017

Aileron Therapeutics Reports Third Quarter 2017 Financial Results

GlobeNewswire November 9, 2017

Aileron Therapeutics Announces Oral Presentations on Lead Product Candidate ALRN-6924 at the 59th American Society of Hematology Annual Meeting

GlobeNewswire November 1, 2017

Aileron Therapeutics Added to the Russell 2000, Russell 3000 and Russell Microcap Indexes

GlobeNewswire September 19, 2017

Aileron Therapeutics Announces Presentation of Preclinical Data with ALRN-6924 at the International Society of Experimental Hematology Annual Scientific Meeting

GlobeNewswire August 24, 2017

Aileron Therapeutics to Present at Canaccord Genuity 37th Annual Growth Conference

GlobeNewswire August 3, 2017

12 Biggest Mid-Day Gainers For Friday

Benzinga.com  July 7, 2017